<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02399306</url>
  </required_header>
  <id_info>
    <org_study_id>scch2015001</org_study_id>
    <nct_id>NCT02399306</nct_id>
  </id_info>
  <brief_title>Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma</brief_title>
  <official_title>A Prospective, Multicenter, Randomized Controlled Study to Compare Chemoradiotherapy With or Without Enteral Nutrition Intervention for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Cancer Hospital and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Province Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sichuan Cancer Hospital and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, prospective, multicenter study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, prospective, multicenter study. The aim of this study was to compare
      the changes of body weight,survival,toxicity,quality of life and opportunistic infection
      frequency in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma between and after
      chemoradiotherapy with or without enteral nutrition therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body Weight Change from baseline to the end of treatment</measure>
    <time_frame>up to 1 month after the treatment</time_frame>
    <description>Body weight change from baseline to the end of treatment = body weight at the end of treatment - baseline body weight.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Body Weight Change during treatment</measure>
    <time_frame>up to 1 month after the treatment</time_frame>
    <description>Maximum body weight change during treatment= the lowest body weight during treatment - baseline body weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood biochemical examination</measure>
    <time_frame>up to 1 month after the treatment</time_frame>
    <description>albumin, haemoglobin,et al</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 3-5 toxicity</measure>
    <time_frame>up to 1 month after the treatment</time_frame>
    <description>Grade 3-5 adverse events as assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0 andthe criteria of the Radiation Therapy Oncology Group ，such as esophagitis、pneumonitis 、hematologic toxicity and infection rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Completion rate of chemoradiotherapy</measure>
    <time_frame>up to 1 month after the treatment</time_frame>
    <description>The proportion of people who complete all treatment as required</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>short-term effect</measure>
    <time_frame>up to 1 month after the treatment</time_frame>
    <description>objective remission rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>at least 2 years</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">222</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <condition>Enteral Nutrition Therapy</condition>
  <condition>Chemoradiotherapy</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>chemoradiotherapy with Enteral Nutrition intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>chemoradiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enteral nutrition</intervention_name>
    <description>Patients in the Trial Group received concurrent chemoradiotherapy and standardized, whole-course enteral nutrition management.</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>Patients receive intensity modulated radiation therapy(IMRT) from week 1 to week 7,once a day, 5 times per week.
Radiotherapy dose：95% gross tumor volume（GTV-T） 60-66 Gy /30-33f，GTV-N 60-66 Gy /30-33f，CTV-T 50-54 Gy /25-27f，CTV-N 50-54 Gy /25-27f.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 75 years old

          -  male or femalePathologically or cytologically proven esophageal squamous cell
             carcinoma

          -  Clinical stage II or stage III

          -  PG-SGA≧2

          -  Karnofsky performance score(KPS) ≧70

          -  Estimated life expectancy of at least 12 weeks

          -  Hemoglobin≥90.0g/dL,white blood cell count（WBC）≥ 4000 cells/mm³,Platelet count≥100,000
             cells/mm³

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 2.5 times upper
             limit of normal,bilirubin normal

          -  Creatinine normal OR creatinine clearance ≥ 60 mL/min

          -  Patients have good compliance to treatment and follow-up of acceptance

          -  Forced expiratory volume in one second（FEV1） ≥ 1.5 litre or ≥ 75% of the reference
             value

          -  the functions of the heart, kidney, liver were basically normal, with no chemotherapy
             and radiotherapy contraindications

        Exclusion Criteria:

          -  Patients with severely bowel function impaired or can not tolerate enteral nutrition

          -  Patients with serious gastrointestinal obstruction, be unable to take food by mouth
             and can not / do not want to a feeding tube inserted

          -  Patients have no risk of malnutrition

          -  Patients have severe malnutrition (weight loss &gt;10% or &lt;30 g/L, BMI&lt;18.5 kg/m2 or
             hemoglobin&lt;90 g/L before the treatment

          -  Patients who have severe vomiting, gastrointestinal bleeding, intestinal obstruction

          -  Patients can not tolerate chemotherapy and radiotherapy

          -  Patients who have distant metastasis

          -  The primary tumor or lymph node already received surgical treatment (except for
             biopsy);

          -  Patient who received radiotherapy for primary tumor or lymph node;

          -  Patient who received chemotherapy or immunotherapy;

          -  Patient who suffered from other malignant tumor;

          -  Patient who have taken other drug test within 1 month;

          -  Pregnant woman or Lactating Women and Women in productive age who refuse to take
             contraception in observation period;

          -  Subject with a severe allergic history or idiosyncratic;

          -  Subject with severe pulmonary and cardiopathic disease history;

          -  Refuse or incapable to sign the informed consent form of participating this trial;

          -  Drug abuse or alcohol addicted;

          -  Subject with a Personality or psychiatric diseases, people with no legal capacity or
             people with limited capacity for civil conduct;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>TAO LI, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Sichuan Cancer Hospital and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sichuan Cancer Hospital &amp; Institute</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 17, 2015</study_first_submitted>
  <study_first_submitted_qc>March 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2015</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sichuan Cancer Hospital and Research Institute</investigator_affiliation>
    <investigator_full_name>LI TAO</investigator_full_name>
    <investigator_title>Section Head</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

